Video

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Related Videos
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
C. Ola Landgren, MD, PhD
Robert M. Rifkin, MD
David Samuel Dicapua Siegel, MD
Marcella Ali Kaddoura, MD
Related Content
Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute
December 12th 2024

Study Finds Quality of Life Maintained With Active Monitoring for DCIS

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Anitocabtagene Autoleucel in Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium
December 11th 2024

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium